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Purpose: Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disorder against melanocytes. Polymorphisms of the
protein  tyrosine  phosphatase  non-receptor  22  gene  (PTPN22)  have  recently  been  reported  to  be  associated  with
susceptibility to several autoimmune diseases. In this study, genetic susceptibility to VKH disease was investigated by
screening for single nucleotide polymorphisms (SNPs) of PTPN22.
Methods: A total of 167 Japanese patients with VKH disease and 188 healthy Japanese controls were genotyped by direct
sequencing methods for six SNPs (rs3811021, rs1217413, rs1237682, rs3761935, rs3789608, and rs2243471) of PTPN22
including the uncoding exons.
Results: The six SNPs in PTPN22 showed no significant association with susceptibility to VKH disease or its ocular,
neurologic, or dermatological manifestation.
Conclusions: Further studies are needed to clarify the genetic mechanisms underlying VKH disease.
Vogt-Koyanagi-Harada (VKH) disease is one of the most
frequent forms of uveitis in Japan [1]. It is characterized as
bilateral  panuveitis  accompanied  by  neurologic  and  skin
lesions [2,3]. This disease is considered to be an autoimmune
disease against melanocytes [4,5]. Though the etiology of
VKH disease still remains unknown, genetic factors may play
an  important  role  in  susceptibility  as  indicated  by  an
established association between VKH disease and specific
human leukocyte antigen (HLA)-DRB1 alleles [6,7].
The protein tyrosine phosphatase non-receptor 22 gene
(PTPN22) is located on chromosome 1p13.3-p13.1, and it
encodes  the  lymphoid-specific  phosphatase  (Lyp)  that  is
important in the negative control of T-cell activation and
development  [8-10].  Recently,  it  was  reported  the  single
nucleotide  polymorphism  (SNP),  R620W  (rs2476601),  in
PTPN22  increased  susceptibility  to  several  autoimmune
diseases including rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), and insulin dependent diabetes mellitus
(IDDM) [11-15]. In the PTPN22 risk variant (rs2476601), this
substitution  disrupts  an  interaction  between  Lyp  and  the
protein tyrosine kinase, Csk, and may translate biologically to
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a potential for ‘hyperreactive’ pathogenic T-cell responses
[8].
This R620W mutation was not observed in the Japanese
population [16,17]. Therefore, in this study, we analyzed six
SNPs, which belong to the same haplotype block as R620W
(rs2476601)  in  PTPN22.  For  the  efficacy  of  the  linkage
analysis, we chose six SNPs of which minor allele frequencies
were more than 15% from the database of Japanese Single
Nucleotide Polymorphisms [18,19].
METHODS
We recruited 167 VKH (72 males and 95 females) patients
and  188  healthy  controls  for  this  study.  All  patients  and
control  subjects  were  Japanese.  Patients  were  diagnosed
according  to  the  “Revised  Diagnostic  Criteria  for  VKH
Disease” [3] at the Uveitis Survey Clinic of the Hokkaido
University Hospital (Sapporo, Japan) and Yokohama City
University  Hospital  (Yokohama,  Japan).  All  patients  and
control subjects were informed of the study’s purpose, and
their consent obtained. The study was approved by the ethics
committee from each institute participating in this study.
DNA  was  prepared  from  peripheral  blood  specimens
using the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo,
Japan).  Six  SNPs  (rs3811021,  rs1217413,  rs1237682,
rs3761935,  rs3789608,  and  rs2243471)  from  the  PTPN22
region were examined (Figure 1). Each of the six SNPs was
amplified  by  standard  polymerase  chain  reactions  (PCRs;
Table  1).  After  purification  using  ExoSAP-IT  (USB
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1115Corporation,  Cleveland,  OH),  the  PCR  products  were
sequenced  with  Big  Dye  Terminator  v3.1  (Applied
Biosystems, Foster City, CA) using either sense or antisense
primers (Table 1). The BigDye XTerminator Purification Kit
(Applied  Biosystems)  was  used  to  purify  the  DNA  from
sequencing  reactions.  The  sequencing  reactions  were
analyzed using an ABI3130 sequencer (Applied Biosystems).
Statistical analysis: For statistical analyses, the Hardy–
Weinberg equilibrium was tested for each SNP among the
control subjects. Genotype frequency differences between the
case and control genotypes were assessed by the χ2 test. The
calculation of linkage disequilibrium (LD) and pair-wise LD
(D’  value)  between  SNPs  of  the  PTPN22  region  and  the
haplotypes was performed with Haploview software, version
3.32.  The  maximum  likelihood  estimates  of  haplotype
frequencies were estimated by pairs of unphased genotypes
using the expectation-maximization (EM) algorithms in the R
package ‘haplo.stats’ [20].
RESULTS
Allele frequencies for the six SNPs covering the gene were in
Hardy–Weinberg  equilibrium  in  both  the  patients  and
controls. The allelic frequency of each SNP in both groups
was  nearly  equal,  and  no  association  was  detected  when
compared independently (odds ratio, OR 1.14–1.35; Table 2).
Stratifying the patients by the presence of diffuse choroiditis,
sunset  glow  fundus,  nummular  chorioretinal  depigmented
spots,  neurologic  auditory  involvement,  meningismus,
tinnitus,  cerebrospinal  fluid  pleocytosis,  or  integumentary
findings also revealed no evidence of association in VKH
disease (data not shown). We calculated pairwise D’ values
for all SNP pairs in PTPN22 (Figure 2). The pairwise D’
values in the gene were nearly 1 among almost all SNP pairs,
indicating the SNPs were highly associated with each other
and the entire PTPN22 was contained within a single LD
block.  Haplotype  analysis  predicted  and  revealed  that
PTPN22  was  not  associated  with  VKH  disease  in  this
Japanese cohort (data not shown).
DISCUSSION
In the present study, we analyzed polymorphisms of the new
candidate  gene,  PTPN22,  in  Japanese  patients  with  VKH
Figure 2. D' score for the six SNPs studied across the  PTPN22
haplotype. Black cells indicate that D' is greater than 0.9. Upper:
patient population, lower: control population. The figure indicates
that the six SNPs were in all the same haplotype block.
Figure 1. PTPN22 structure with two transcript isoforms and six SNP. Six SNP variants with minor allele frequencies 15% from the database of
Japanese Single Nucleotide Polymorphisms. The black and white areas in the exons indicate the UTR and coding region, respectively.
TABLE 1. PCR PRIMERS FOR PTPN22 SNPS.
SNP position Primers Product size (bp) sequence primer
rs3811021 (SNP1) 114158186 F: TGGGTTGCAATACAAACTGCTC 600 Forward
R: TCAATTTGCCCTATTGGACTTC
rs1217413 (SNP2) 114159273 F: TTGCAGGTGTACTTGCAGCC 552 Forward
R: TTGAAGGATTTCTGGACCGAC
rs1237682 (SNP3) 114165627 F: AAGGAGGCACAGATTCCACAC 589 Forward
R: TGACCATGCCAATATACCAACTG
rs3761935 (SNP4) 114174051 F: AAAGTTTCCGGCATGTTTCC 595 Reverse
R: TGGTGATTGTCGGCTAAGATTG
rs3789608 (SNP5) 114199311 F: CATCATGGTCTGGCCAATTC 589 Forward
R: TGAGGTGGAGTTCTAACCACAAG
rs2243471 (SNP6) 114207525 F: GACAAGACTGAATTGTACGAGCG 577 Forward
R: CACCATCTCCAGCCTCTCAC
The position of the SNPs is cited from the NCBI database.
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1116disease. The gene encodes an important negative regulator of
T  cell  activation  [9].  An  SNP  of  PTPN22,  R620W
(rs2476601)  was  reported  to  be  associated  with  several
autoimmune diseases such as RA, SLE, and IDDM [11,12,
14,15].  However,  this  SNP,  which  disrupts  an  interaction
between Lyp and the protein tyrosine kinase, Csk, does not
exist as a polymorphism in the Japanese population [9,10,
12]. Therefore, in this study, we examined six other SNPs to
evaluate the susceptibility locus of PTPN22. HLA-DRB1 is a
common  genetic  factor  in  autoimmune  diseases  (RA  and
IDDM).  Therefore,  there  may  be  other  common  genetic
factors in VKH disease [21].
VKH disease is considered to be an autoimmune disease
against  melanocytes  [2-5].  In  early  studies,  activated  T
lymphocytes  were  elevated  and  attacked  melanocytes  of
ocular choroidal tissue in patients in the active phase of VKH
disease  [22].  Antigen-specific  T-cell  assay  revealed  that
peptide  fragments  of  the  tyrosinase  family  proteins
(tyrosinase, tyrosinase related protein 1 and 2) proliferated in
T  lymphocytes  collected  from  VKH  patients  [4,5].  These
proteins are found in human melanocytes. These antigen-
specific T cell responses were detected in cells collected from
HLA-DRB1*04  positive  VKH  patients  only  but  not  from
HLA-DRB1*04 negative patients or HLA-DRB1*04 positive
healthy people [7,23]. In the Japanese population, 40% of
healthy people have HLA-DRB1*04 [7]. However, people
having VKH disease represent only 0.01% of the Japanese
population [1,7,24,25]. In addition, some patients with VKH
disease are HLA-DRB1*04 negative [7]. Thus, it is believed
HLA-DRB1*04 is a major susceptible gene in VKH disease.
However, other minor genetic factors still remain unclear. To
find other susceptible genes, we studied the tyrosinase gene
(TYR), tyrosinase related protein 1 gene (TYRP1), tyrosinase
related protein 2 gene (TYRP2), and interferon (IFN-γ), but
we could not find any association with these genes and VKH
disease  [7,26].  Genetic  influences  of  VKH  were  also
investigated in other countries, but the etiology of the disease
seems to be unresolved [27-29].
In this study, we found no association between PTPN22
and  VKH  disease  in  the  individuals  studied.  Our  results
suggest that further molecular genetic studies are needed to
detect  novel  genetic  loci  and  predisposing  genes  and  to
elucidate  the  true  genetic  mechanisms  underlying  VKH
disease.
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